NCT05807815

Brief Summary

Oxygen therapy is the most common treatment modality for patients with hypoxemia in intensive care units, but target values for normoxemia are not clearly defined. Therefore, iatrogenic hyperoxemia is a very common situation. In intensive care units, FiO2 is usually adjusted according to hypoxia and hyperoxia is ignored in patients under mechanical ventilator support. Even though there are many side effects reported related to hyperoxemia and hyperoxemia is shown to be related to worse outcome than expected; clinicians still observe hyperoxemia frequently. Continuous ORi monitoring can be used for detecting and preventing hyperoxia. The ability to perform FiO2 titration with ORi may be an appropriate monitoring management to prevent the harmful effects of hyperoxia. In this study, it was aimed to investigate the effectiveness of ORi-guided FiO2 titration in preventing hyperoxia in patients undergoing mechanical ventilation in the intensive care unit and to determine the incidence of hyperoxia.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
60

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Mar 2021

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2021

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2023

Completed
12 days until next milestone

Study Completion

Last participant's last visit for all outcomes

March 13, 2023

Completed
2 days until next milestone

First Submitted

Initial submission to the registry

March 15, 2023

Completed
27 days until next milestone

First Posted

Study publicly available on registry

April 11, 2023

Completed
Last Updated

April 11, 2023

Status Verified

March 1, 2023

Enrollment Period

2 years

First QC Date

March 15, 2023

Last Update Submit

March 29, 2023

Conditions

Keywords

HyperoxiaFraction of inspired oxygenIntensive care unit

Outcome Measures

Primary Outcomes (1)

  • Correlation of FiO2 and ORi value

    Correlation of FiO2 value and ORi value. FiO2 adjusted until ORi reaches to zero and %95\<oxygen saturation≤%98

    Up to 24 weeks

Secondary Outcomes (4)

  • Fraction of inspired oxygen (FiO2)

    Up to 48 hours

  • Mean arterial blood pressure (MAP)

    Up to 48 hours

  • Heart rate (HR)

    Up to 48 hours

  • Positive end-expiratory pressure (PEEP)

    Up to 48 hours

Study Arms (2)

Control group

NO INTERVENTION

Patients with oxygen saturation \> 97% will only be observed. ORi values will be recorded blindly from the clinician. Adjustments to be made in FiO2 will be determined by the intensive care doctor independently of the study, and only observation will be made in this group.

ORi+SpO2 (oxygen saturation) group

ACTIVE COMPARATOR

Fraction of inspired oxygen (FiO2) is titrated guided by oxygen saturation in that range; %95\<oxygen saturation≤%98

Procedure: Titration of fraction of inspired oxygen (FiO2) guided by ORI and oxygen saturation

Interventions

FiO2 will be titrated by reducing 10% if Ori\>0.01 and oxygen saturation ≥ 98% until Ori is 0.00. FiO2 will not be changed if Ori is 0.00 and %95\<oxygen saturation≤%98 FiO2 will be increased by 10% if oxygen saturation \<95 or PaO2\<60 mmHg

ORi+SpO2 (oxygen saturation) group

Eligibility Criteria

Age18 Years - 85 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients older than 18 years,
  • Patients whose oxygen saturation \>97%
  • Patients that have invasive arterial monitorization

You may not qualify if:

  • Patients younger than 18
  • Patients that need to be treated with high doses of vasopressors,
  • Patients having peripheric hypoperfusion,
  • Hemodynamically unstable patients,
  • Patients with hemoglobinopathy,
  • Pregnancy,
  • Morbid obesity (bmi\>40 kg/m2),
  • Patients with arrythmia that can result in hemodynamic instability, patients with acute coronary syndrome
  • Acute respiratory failure or ARDS.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Tepecik Research and Training Hospital

Izmir, Konak, 35110, Turkey (Türkiye)

Location

Related Publications (5)

  • de Graaff AE, Dongelmans DA, Binnekade JM, de Jonge E. Clinicians' response to hyperoxia in ventilated patients in a Dutch ICU depends on the level of FiO2. Intensive Care Med. 2011 Jan;37(1):46-51. doi: 10.1007/s00134-010-2025-z. Epub 2010 Sep 28.

    PMID: 20878146BACKGROUND
  • Rincon F, Kang J, Maltenfort M, Vibbert M, Urtecho J, Athar MK, Jallo J, Pineda CC, Tzeng D, McBride W, Bell R. Association between hyperoxia and mortality after stroke: a multicenter cohort study. Crit Care Med. 2014 Feb;42(2):387-96. doi: 10.1097/CCM.0b013e3182a27732.

    PMID: 24164953BACKGROUND
  • Mach WJ, Thimmesch AR, Pierce JT, Pierce JD. Consequences of hyperoxia and the toxicity of oxygen in the lung. Nurs Res Pract. 2011;2011:260482. doi: 10.1155/2011/260482. Epub 2011 Jun 5.

    PMID: 21994818BACKGROUND
  • Scheeren TWL, Belda FJ, Perel A. Correction to: The oxygen reserve index (ORI): a new tool to monitor oxygen therapy. J Clin Monit Comput. 2018 Jun;32(3):579-580. doi: 10.1007/s10877-018-0104-9.

    PMID: 29445905BACKGROUND
  • Yoshida K, Isosu T, Noji Y, Ebana H, Honda J, Sanbe N, Obara S, Murakawa M. Adjustment of oxygen reserve index (ORi) to avoid excessive hyperoxia during general anesthesia. J Clin Monit Comput. 2020 Jun;34(3):509-514. doi: 10.1007/s10877-019-00341-9. Epub 2019 Jun 22.

    PMID: 31227971BACKGROUND

MeSH Terms

Conditions

Hyperoxia

Interventions

Oxygen Saturation

Condition Hierarchy (Ancestors)

Signs and Symptoms, RespiratorySigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Metabolism

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
associated professor

Study Record Dates

First Submitted

March 15, 2023

First Posted

April 11, 2023

Study Start

March 1, 2021

Primary Completion

March 1, 2023

Study Completion

March 13, 2023

Last Updated

April 11, 2023

Record last verified: 2023-03

Locations